MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
443 M |
Market Cap[1] |
$ 35.2 B |
EBITDA (LTM) |
$ 487 M |
P/E (LTM) |
12.572139 |
P/S (LTM) |
3.55101 |
EPS (LTM) |
6.03 |
Zoetis is a global leader in animal health and veterinary medicine, providing a wide range of products and services to improve animal health, including medicines, vaccines, diagnostic tests, and animal health management programs. The company was created in 2013 after being spun off from Pfizer Inc., and is headquartered in New Jersey, USA.
Zoetis works with farmers, veterinarians, and other professionals in the livestock and animal health industries around the world. The company is committed to innovation and developing new products and services to improve animal health and provide more effective animal health management. Zoetis is also actively involved in social responsibility, supporting various charitable organizations and programs.
Today, Zoetis has a presence in over 100 countries and serves millions of animals. The company is constantly striving to improve its products and services to meet the needs of its customers and partners.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ММЦБ
GEMA
|
- | - | - | MOEX | Russia |
 |
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | USA |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | Russia |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX | Russia |
 |
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | Russia |
 |
Промомед
PRMD
|
- | - | - | MOEX | Russia |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market |  Canada |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | USA |
 |
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market |  Niderland |
 |
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | USA |
 |
Exicure
XCUR
|
$ 1.12 | 0.88 % | $ 7.05 M | Nasdaq Capital Market | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.04 | 1.36 % | $ 104 M | Nasdaq Global Market |  France |
 |
AbCellera Biologics
ABCL
|
$ 11.8 | 2.51 % | $ 3.52 B | Nasdaq Global Select Market | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 55.9 | 0.22 % | $ 7.48 B | Nasdaq Global Select Market,SPB | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 54.68 | 1.65 % | $ 10.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.53 | 3.93 % | $ 1.83 B | Nasdaq Global Select Market | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.63 | 0.64 % | $ 44.3 M | Nasdaq Capital Market |  Israel |
 |
Jaguar Health
JAGX
|
$ 3.53 | 9.81 % | $ 8.23 M | Nasdaq Capital Market | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.62 | 3.05 % | $ 206 M | NYSE American | Israel |
 |
uniQure N.V.
QURE
|
$ 21.78 | 7.39 % | $ 1.25 B | Nasdaq Global Select Market | Niderland |
 |
Stoke Therapeutics
STOK
|
$ 24.17 | 5.8 % | $ 1.43 B | Nasdaq Global Select Market,SPB | USA |
 |
Xencor
XNCR
|
$ 22.85 | 2.61 % | $ 1.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Annexon
ANNX
|
$ 3.41 | 1.09 % | $ 529 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.76 | 0.54 % | $ 2.9 M | NYSE American | Israel |
 |
Incyte Corporation
INCY
|
$ 113.07 | 0.03 % | $ 22.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Mesoblast Limited
MESO
|
$ 13.28 | 1.16 % | $ 16 B | Nasdaq Global Select Market |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
$ 9.28 | 5.1 % | $ 746 M | Nasdaq Global Select Market | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 499.74 | 0.08 % | $ 128 B | Nasdaq Global Select Market,SPB | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 225.25 | 0.42 % | $ 13.7 B | Nasdaq Global Select Market |  Danmark |
 |
Axon Enterprise
AXON
|
$ 390.29 | 2.15 % | $ 30.5 B | Nasdaq Global Select Market,SPB | USA |
 |
AbbVie
ABBV
|
$ 285.42 | 0.71 % | $ 505 B | NYSE,SPB | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.72 | 2.35 % | $ 97.8 M | Nasdaq Global Select Market,SPB | USA |
 |
Altimmune
ALT
|
$ 2.2 | 2.16 % | $ 194 M | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.22 | 2.39 % | $ 809 M | Nasdaq Global Select Market | Canada |
 |
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 11.84 | 0.87 % | $ 1.06 B | Nasdaq Capital Market | USA |
 |
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Codexis
CDXS
|
$ 1.24 | 5.43 % | $ 108 M | Nasdaq Global Select Market | USA |
 |
Cullinan Management
CGEM
|
$ 12.93 | 2.64 % | $ 779 M | Nasdaq Global Select Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.96 | 4.0 % | $ 183 M | Nasdaq Global Market,SPB | Israel |
 |
Cellectar Biosciences
CLRB
|
$ 1.14 | 0.84 % | $ 2.97 M | Nasdaq Capital Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.32 | 0.17 % | $ 4.7 B | Nasdaq Global Market |  Irlanda |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.02 | 0.49 % | $ 11.5 M | Nasdaq Capital Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.28 | 3.25 % | $ 402 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.